Benjamin Jiang is a corporate partner in the Boston office of Kirkland & Ellis LLP. His practice focuses on mergers and acquisitions and related corporate advice for both public and private companies in biopharmaceutical, technology and adjacent sectors.
Experience
Representative Matters
Prior to joining Kirkland, Benjamin was involved in the following representative matters:
SiteOne Therapeutics in its pending acquisition by Eli Lilly for up to $1 billion
AspenTech in its $11 billion combination with the industrial software business of Emerson Electric and the special committee in its subsequent $7.2 billion sale to Emerson of all shares of AspenTech not already owned by Emerson
The special committee of the board of directors of R1 RCM in its sale to investment funds affiliated with TowerBrook Capital Partners and Clayton Dubilier & Rice for an enterprise value of $8.9 billion
EyeBio in its sale to Merck for $1.3 billion up front and up to $1.7 billion in future milestone payments
Mirati Therapeutics in its sale to Bristol Myers Squibb for up to $5.8 billion
Intercept Pharmaceuticals in its sale to Alfasigma for approximately $800 million
BELLUS Health in its $2 billion sale to GSK
Ambrx Biopharma in its $2 billion acquisition by Johnson & Johnson
Alcon in its $753 million acquisition of Aerie Pharmaceuticals
Strongbridge Biopharma in its sale to Xeris Pharmaceuticals for $267 million
Pandion Therapeutics in its sale to Merck & Co. for $1.85 billion
Stemline Therapeutics in its sale to Menarini Group for up to $677 million
Ionis Pharmaceuticals in its acquisition of the remaining outstanding stake of Akcea Therapeutics for $500 million
Gilead Sciences in its $4.9 billion acquisition of Forty Seven
Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion
